Literature DB >> 15672325

Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene.

Ornit Chiba-Falek1, Jeffrey A Kowalak, Mark E Smulson, Robert L Nussbaum.   

Abstract

Alleles at NACP-Rep1, the polymorphic microsatellite repeat located approximately 10 kb upstream of the alpha -synuclein gene (SNCA), are associated, in some reports, with differing risks of sporadic Parkinson disease (PD). We showed previously that NACP-Rep1 acts as a negative modulator of SNCA transcription, with an effect that varied threefold among different NACP-Rep1 alleles. Given that duplications and triplications of SNCA have been implicated in familial Parkinson disease (PD), even a 1.5-2-fold increase in alpha -synuclein expression may, over many decades, contribute to PD. Thus, the association of different NACP-Rep1 alleles with PD may be a consequence of polymorphic differences in transcriptional regulation of SNCA. Here we aimed to identify the factor(s) that bind to NACP-Rep1 and potentially contribute to SNCA transcriptional modulation, by pulling down proteins that bind to NACP-Rep1 and identifying them by mass spectrometry. One of these proteins was poly-(ADP-ribose) transferase/polymerase-1 (PARP-1), a DNA-binding protein and transcriptional regulator. Electrophoresis mobility shift and chromatin immunoprecipitation assays showed specific binding of PARP-1 to NACP-Rep1. Inhibition of PARP-1's catalytic domain increased the endogenous SNCA mRNA levels in cultured SH-SY5Y cells. Furthermore, PARP-1 binding to NACP-Rep1 specifically reduced the transcriptional activity of the SNCA promoter/enhancer in luciferase reporter assays. This down-regulation effect of PARP-1 depended on NACP-Rep1 being present in the construct and was abrogated by inhibiting PARP-1's catalytic activity with 3-aminobenzamide. The association of different NACP-Rep1 alleles with PD may be mediated, in part, by the effect of PARP-1, as well as other factors, on SNCA expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15672325      PMCID: PMC1196399          DOI: 10.1086/428655

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  48 in total

1.  Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system.

Authors:  O Chiba-Falek; R L Nussbaum
Journal:  Hum Mol Genet       Date:  2001-12-15       Impact factor: 6.150

Review 2.  Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.

Authors:  D D'Amours; S Desnoyers; I D'Silva; G G Poirier
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

3.  Poly(ADP-ribose) polymerase is a B-MYB coactivator.

Authors:  M N Cervellera; A Sala
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

4.  A Drosophila model of Parkinson's disease.

Authors:  M B Feany; W W Bender
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

5.  Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice.

Authors:  F J Oliver; J Ménissier-de Murcia; C Nacci; P Decker; R Andriantsitohaina; S Muller; G de la Rubia; J C Stoclet; G de Murcia
Journal:  EMBO J       Date:  1999-08-16       Impact factor: 11.598

6.  Inhibition of nuclear receptor signalling by poly(ADP-ribose) polymerase.

Authors:  T Miyamoto; T Kakizawa; K Hashizume
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

7.  Identification of poly(ADP-ribose) polymerase as a transcriptional coactivator of the human T-cell leukemia virus type 1 Tax protein.

Authors:  M G Anderson; K E Scoggin; C M Simbulan-Rosenthal; J A Steadman
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

Authors:  E Masliah; E Rockenstein; I Veinbergs; M Mallory; M Hashimoto; A Takeda; Y Sagara; A Sisk; L Mucke
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

9.  Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor?

Authors:  E K Tan; T Matsuura; S Nagamitsu; M Khajavi; J Jankovic; T Ashizawa
Journal:  Neurology       Date:  2000-03-14       Impact factor: 9.910

10.  Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype.

Authors:  R Krüger; A M Vieira-Saecker; W Kuhn; D Berg; T Müller; N Kühnl; G A Fuchs; A Storch; M Hungs; D Woitalla; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Ann Neurol       Date:  1999-05       Impact factor: 10.422

View more
  38 in total

1.  SNCA variant associated with Parkinson disease and plasma alpha-synuclein level.

Authors:  Ignacio F Mata; Min Shi; Pinky Agarwal; Kathryn A Chung; Karen L Edwards; Stewart A Factor; Douglas R Galasko; Carmen Ginghina; Alida Griffith; Donald S Higgins; Denise M Kay; Hojoong Kim; James B Leverenz; Joseph F Quinn; John W Roberts; Ali Samii; Katherine W Snapinn; Debby W Tsuang; Dora Yearout; Jing Zhang; Haydeh Payami; Cyrus P Zabetian
Journal:  Arch Neurol       Date:  2010-11

2.  Accurate prediction of a minimal region around a genetic association signal that contains the causal variant.

Authors:  Zoltán Bochdanovits; Javier Simón-Sánchez; Marianne Jonker; Witte J Hoogendijk; Aad van der Vaart; Peter Heutink
Journal:  Eur J Hum Genet       Date:  2013-06-05       Impact factor: 4.246

3.  Complex Effects of the ZSCAN21 Transcription Factor on Transcriptional Regulation of α-Synuclein in Primary Neuronal Cultures and in Vivo.

Authors:  Georgia Dermentzaki; Nikolaos Paschalidis; Panagiotis K Politis; Leonidas Stefanis
Journal:  J Biol Chem       Date:  2016-02-23       Impact factor: 5.157

Review 4.  Structural variants in SNCA gene and the implication to synucleinopathies.

Authors:  Ornit Chiba-Falek
Journal:  Curr Opin Genet Dev       Date:  2017-03-02       Impact factor: 5.578

5.  The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease.

Authors:  Colton Linnertz; Michael W Lutz; John F Ervin; Jawara Allen; Natalie R Miller; Kathleen A Welsh-Bohmer; Allen D Roses; Ornit Chiba-Falek
Journal:  Hum Mol Genet       Date:  2014-04-28       Impact factor: 6.150

6.  Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells.

Authors:  Li-Wen Ko; Hwai-Hwa C Ko; Wen-Lang Lin; Jayanranyan G Kulathingal; Shu-Hui C Yen
Journal:  J Neuropathol Exp Neurol       Date:  2008-11       Impact factor: 3.685

7.  GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein.

Authors:  Clemens R Scherzer; Jeffrey A Grass; Zhixiang Liao; Imelda Pepivani; Bin Zheng; Aron C Eklund; Paul A Ney; Juliana Ng; Meghan McGoldrick; Brit Mollenhauer; Emery H Bresnick; Michael G Schlossmacher
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-31       Impact factor: 11.205

8.  Positive transcriptional regulation of the human micro opioid receptor gene by poly(ADP-ribose) polymerase-1 and increase of its DNA binding affinity based on polymorphism of G-172 -> T.

Authors:  Takeshi Ono; Toshio Kaneda; Akihiro Muto; Tadashi Yoshida
Journal:  J Biol Chem       Date:  2009-05-15       Impact factor: 5.157

9.  Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain.

Authors:  Kenneth D Cronin; Dongliang Ge; Paul Manninger; Colton Linnertz; Anna Rossoshek; Bonnie M Orrison; David J Bernard; Omar M A El-Agnaf; Michael G Schlossmacher; Robert L Nussbaum; Ornit Chiba-Falek
Journal:  Hum Mol Genet       Date:  2009-06-04       Impact factor: 6.150

10.  Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues.

Authors:  Colton Linnertz; Laura Saucier; Dongliang Ge; Kenneth D Cronin; James R Burke; Jeffrey N Browndyke; Christine M Hulette; Kathleen A Welsh-Bohmer; Ornit Chiba-Falek
Journal:  PLoS One       Date:  2009-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.